Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis

Author:

Bai YupingORCID,He Tingting,Zhang LiyanORCID,Liu Qianqian,Yang JingORCID,Zhao Ziru,Yang Kehu,Zhang Min

Abstract

ObjectivesWe aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3+) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources of heterogeneity of the results.DesignSystematic review and meta-analysis.Data sourcesWe searched the Cochrane Library, PubMed, Embase and Web of Science databases up to 5 December 2021.Eligibility criteriaWe included studies that analysed the prognostic significance of FOXP3+ Tregs in DLBCL. We included studies reported in Chinese or English that reported HRs and related 95% CIs for prognosis.Data extraction and synthesisWe extracted data from eligible studies. HRs and 95% CIs were used to assess the prognostic value.ResultsFourteen eligible studies were identified. FOXP3+ Treg expression was not associated with overall survival (OS) (HR=0.72, 95% CI 0.45 to 1.16) or progression-free survival (HR=0.86, 95% CI 0.54 to 1.38). The three approaches used to measure FOXP3+ Treg expression (pinteraction<0.001) may be the source of the heterogeneity of the results. Subgroup analysis found that a higher expression of FOXP3+ Tregs was associated with better OS in all populations and in Asians when FOXP3+ Treg expression was measured by the number of positive cells (HR=0.36 (95% CI 0.22 to 0.58) in the former, HR=0.33 (95% CI 0.20 to 0.55) in the latter) or the percentage of positive cells (HR=0.49 (95% CI 0.27 to 0.89) in the former, HR=0.38 (95% CI 0.21 to 0.70) in the latter). However, when measured by the score, inverse results were found (HR=1.56, 95% CI 1.01 to 2.42).ConclusionsApproaches to measuring FOXP3+ Treg expression might be the major source of heterogeneity in studies of the prognostic significance of FOXP3+ Tregs in DLBCL. FOXP3+ Treg expression might be used to predict the prognosis of patients with DLBCL when FOXP3+ Treg expression is calculated by the number or the percentage of positive cells, especially in Asian populations.

Funder

National Natural Science Foundation of China

International Cooperation Exchange Project of Gansu Province

CAS ‘Light of West China’

Publisher

BMJ

Subject

General Medicine

Reference39 articles.

1. The Histological and Biological Spectrum of Diffuse Large B-Cell Lymphoma in the World Health Organization Classification

2. Swerdlow S , Campo E , Harris NL . World health organisation classification of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008.

3. The progression of prognostic markers in diffuse large B cell lymphoma;Wang;Int J Radiat Med Nucl Med,2020

4. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era;Huang;Ann Hematol,2013

5. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma];Song;Zhonghua Xue Ye Xue Za Zhi,2018

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3